हेमेटोलॉजी और थ्रोम्बोम्बोलिक रोगों का जर्नल
खुला एक्सेस

अमूर्त

Reducing Risks in Large Volume Liposuction: The Role of Oral Anticoagulants in Preventing Thromboembolism

Emmanuel de La Cruz*, Brad P. Delacruz

Objective: This retrospective study aimed to analyze the outcomes of patients aged 21 years or older who underwent Large Volume Liposuction (LVL) using either the Ultrasonic Assisted Liposuction (UAL) or Synchronous-Energy Assisted Liposuction (SEAL) technique at a single surgeon's institution.

Methods: A total of 88 patients aged 21 years or older, with a Body Mass Index (BMI) over 30 kg/m² and who underwent LVL exceeding 5 liters, were included in this study. The average BMI of the patients included was 35.4 kg/m², with a mean weight of 218.4 pounds. The average Caprini score, used for assessing the risk of Venous Thromboembolism (VTE), was 3.68. Thromboembolism prophylaxis was administered to all patients in the form of subcutaneous heparin 5000 units and an oral anticoagulant (Rivaroxaban) given 24 hours after surgery. The incidence of VTE, hematoma, and significant bleeding was observed.

Results: Notably, there were no instances of venous thromboembolism, hematoma, or significant bleeding observed among the patients aged 21 years or older who underwent LVL. Minimal bleeding was noted, with a modest decrease of 1.2 g/dL in hemoglobin levels and 3.02% in hematocrit levels.

Conclusion: Our findings suggest that the utilization of UAL or SEAL techniques, in conjunction with appropriate thromboembolism prophylaxis, effectively mitigates the risk of VTE, hematoma, and significant bleeding in patients aged 21 years or older undergoing LVL. The observed minimal decrease in hemoglobin and hematocrit levels further supports the notion that the risk of excessive bleeding is low. Nonetheless, prudent monitoring and management of these levels remain advisable. Further studies are warranted to investigate the long-term implications of these techniques on patient outcomes within this specific age group.